Amarin (AMRN)
(Delayed Data from NSDQ)
$0.61 USD
-0.01 (-1.06%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $0.61 0.00 (-0.72%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 141 - 160 ( 365 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Dial In to Our Two Expert Calls This Week to Learn About FSGS and Omega-3s
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Yas'' Weekly Recap of Our Key Notes and 8 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
4Q19 - Vascepa Continues to Be Head - Shoulders Above Other CVD Drugs
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
With Vascepa in Omega-3 Pole Position, Can Track Conditions Become a Factor? Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Dial-in Today at 11AM to Our CVD Expert Call with Dr. John Kastelein - Part 1
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Do Not Miss Our Call Tomorrow with CVD Guru, Dr. John Kastelein - Part 1
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Positive CHMP Opinion, As Vascepa Tries on Glass Slipper for EU Opportunity
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare -Join Our Two Doc Calls: How Omega-3s/Fatty Acids Differ in the Heart and Liver
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare -Join Our 1Q20 Doc Call Series in PWS, NASH, Omega-3s and Contraception
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare- Yas'' Weekly Recap of Our Key Notes and Upcoming Events
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Encouraged by Reiterated 2020 Revenue Guidance and Vascepa Commercial Outlook; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A